ArticlePloS one2020
Evidence of recombination of vaccine strains of lumpy skin disease virus with field strains, causing disease.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Lumpy Skin Disease: A Systematic Review of Mode of Transmission, Risk of Emergence and Risk Entry Pathway.Viruses · 2023Pooled it
- Article
- Clinical study and the diagnosis of lumpy skin disease in cattle using genomic, immunological, and pathological indicators.Frontiers in veterinary science · 2026Article
- Lumpy Skin Disease Virus Infected Calves Showing Multisystemic Vasculitis on Postmortem Examination: A Summary of Six Cases.Transboundary and emerging diseases · 2026Article
- Article
- Article
- Genetic Characterization of the First Case of Lumpy Skin Disease in Singapore, 2022.Veterinary sciences · 2025Article
- Lumpy Skin Disease Virus Pathogenesis: Viral Protein Functions and Comparative Insights from Vaccinia Virus.Animals : an open access journal from MDPI · 2025Review
- Lumpy Skin Disease Virus (LSDV): evaluating global impact, Ethiopia's response strategies, and the promise of gamma-ray inactivated vaccines.Tropical animal health and production · 2025Review
- Novel multi-epitope vaccine candidate for lumpy skin disease: Computational design and recombinant expression.Veterinary world · 2025Article
- A Genome-Wide Screening of Novel Immunogenic TrLSDV103 Protein of Lumpy Skin Disease Virus and Its Application for DIVA.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Monitoring of genetic alterations of lumpy skin disease virus in cattle after vaccination in Thailand.Journal of animal science and technology · 2025Article
- Lumpy skin disease: A growing threat to the global livestock industry.Open veterinary journal · 2025Review
- Replication and Virulence in Cattle of the First Lumpy Skin Disease Virus Isolated in Xinjiang, China (2019).Transboundary and emerging diseases · 2025Article
- The Safety and Efficacy of New DIVA Inactivated Vaccines Against Lumpy Skin Disease in Calves.Vaccines · 2024Article
- Challenges in the Application of African Swine Fever Vaccines in Asia.Animals : an open access journal from MDPI · 2024Article
- The first outbreak of Lumpy Skin Disease in Indonesia.Tropical animal health and production · 2024Article
- Characterization and molecular identification of the lumpy skin disease virus in cattle in the Mekong Delta of Vietnam.Open veterinary journal · 2024Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination against lumpy skin disease (LSD) is crucial for maintaining the health of animals and the economic sustainability of farming. Either homologous vaccines consisting of live attenuated LSD virus (LSDV) or heterologous vaccines consisting of live attenuated sheeppox or goatpox virus (SPPV/GPPV) can be used for control of LSDV. Although SPPV/GTPV-based vaccines exhibit slightly lower efficacy than live attenuated LSDV vaccines, they do not cause vaccine-induced viremia, fever, and clinical symptoms of the disease following vaccination, caused by the replication capacity of live attenuated LSDVs. Recombination of capripoxviruses in the field was a long-standing hypothesis until a naturally occurring recombinant LSDV vaccine isolate was detected in Russia, where the sheeppox vaccine alone is used. This occurred after the initiation of vaccination campaigns using LSDV vaccines in the neighboring countries in 2017, when the first cases of presumed vaccine-like isolate circulation were documented with concurrent detection of a recombinant vaccine isolate in the field. The follow-up findings presented herein show that during the period from 2015 to 2018, the molecular epidemiology of LSDV in Russia split into two independent waves. The 2015-2016 epidemic was attributable to the field isolate. Whereas the 2017 epidemic and, in particular, the 2018 epidemic represented novel disease importations that were not genetically linked to the 2015-2016 field-type incursions. This demonstrated a new emergence rather than the continuation of the field-type epidemic. Since recombinant vaccine-like LSDV isolates appear to have entrenched across the country's border, the policy of using certain live vaccines requires revision in the context of the biosafety threat it presents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.